말토오스

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H315：피부에 자극을 일으킴

  H319：눈에 심한 자극을 일으킴

• 예방조치문구

  P264：취급 후에는 손을 철저히 씻으시오.

  P264：취급 후에는 손을 철저히 씻으시오.

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P302+P352：피부에 묻으면 다량의 물로 씻으시오.

  P305+P351+P338：눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

  P332+P313：피부 자극이 생기면 의학적인 조치· 조언을 구하시오.

  P337+P313：눈에 대한 자극이 지속되면 의학적인 조치· 조언를 구하시오.

말토오스 화학적 특성, 용도, 생산

• 화학적 성질

  Maltose occurs as white crystals or as a crystalline powder. It is odorless and has a sweet taste approximately 30% that of sucrose.

• 출처

  Maltose also is formed by yeast during breadmaking.

• 용도

  Maltose is a sweetener formed by the enzymatic action of yeast on starch. it consists of two dextrose molecules. maltose dissolves and crystallizes slowly in aqueous solutions, and is less sweet and more stable than sucrose. it is used in combination with dextrose in bread and in instant foods, and is also used in pancake syrups.

• 정의

  A sugar found in germinating cereal seeds. It is a disaccharide composed of two glucose units. Maltose is an important intermediate in the enzyme hydrolysis of starch. It is further hydrolyzed to glucose.

• 생산 방법

  Maltose monohydrate is prepared by the enzymatic degradation of starch.

• Pharmaceutical Applications

  Maltose is a disaccharide carbohydrate widely used in foods and pharmaceuticals. In parenteral products, maltose may be used as a source of sugar, particularly for diabetic patients.
  Crystalline maltose is used as a direct-compression tablet excipient in chewable and nonchewable tablets.

• Safety Profile

  Experimental teratogenic and reproductive effects. Questionable carcinogen with experimental tumorigenic data. When heated to decomposition it emits acrid smoke and irritating fumes.

• Safety

  Maltose is used in oral and parenteral pharmaceutical formulations and is generally regarded as an essentially nontoxic and nonirritant material. However, there has been a single report of a liver transplantation patient with renal failure who developed hyponatremia following intravenous infusion of normal immunoglobulin in 10% maltose. The effect, which recurred on each of four successive infusions, resembled that of hyperglycemia and was thought to be due to accumulation of maltose and other osmotically active metabolites in the extracellular fluid.
  LD₅₀ (mouse, IV): 26.8 g/kg
  LD₅₀ (mouse, SC): 38.6 g/kg
  LD₅₀ (rabbit, IV): 25.2 g/kg
  LD₅₀ (rat, IP): 30.6 g/kg
  LD₅₀ (rat, IV): 15.3 g/kg
  LD₅₀ (rat, oral): 34.8 g/kg

• 저장

  Maltose should be stored in a well-closed container in a cool, dry place.

• 비 호환성

  Maltose may react with oxidizing agents. A Maillard-type reaction may occur between maltose and compounds with a primary amine group, e.g. glycine, to form brown-colored products.

• Regulatory Status

  In the USA, maltose is considered as a food by the FDA and is therefore not subject to food additive and GRAS regulations. Included in the FDA Inactive Ingredients Database (oral solutions). Included in the Canadian List of Acceptable Non-medicinal Ingredients. Included in parenteral products available in a number of countries worldwide.

말토오스 준비 용품 및 원자재

말토오스 공급 업체

Global(365)Suppliers

말토오스 관련 검색